Perjeta is a medicine used to treat HER2-positive breast cancer, usually together with trastuzumab and chemotherapy. It is given as an infusion into a vein. It works by attaching to the HER2 protein on cancer cells and blocking the signals that make them grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Perjeta (Pertuzumab) for Breast Cancer?
Pertuzumab, sold as Perjeta, is a targeted treatment for HER2-positive breast cancer. HER2-positive means the cancer cells carry unusually large amounts of HER2 (human epidermal growth factor receptor 2), a protein that drives cell growth. Pertuzumab is used only after a laboratory test on tumor tissue confirms HER2-positive status, and it is never given on its own: it is combined with trastuzumab (Herceptin), another HER2-targeted antibody, and chemotherapy. It has three approved roles in adults. Before surgery (called neoadjuvant treatment), it is used for early breast cancer that is larger than 2 centimeters or has reached nearby lymph nodes, and for locally advanced or inflammatory breast cancer, to shrink the cancer as part of a complete treatment plan. After surgery (adjuvant treatment), it is used for early breast cancer with a high risk of coming back. And for metastatic breast cancer, meaning cancer that has spread to distant parts of the body, it is used as a first treatment together with docetaxel, a chemotherapy drug, in people who have not yet had HER2-targeted medicines or chemotherapy for the metastatic disease. Phesgo is a separate product that combines pertuzumab and trastuzumab in a single injection given under the skin. It is approved for the same three situations.
HER2 sits on the surface of cells and relays signals that tell them to grow and divide. To send its strongest signals, HER2 pairs up with related receptors on the same cell. In HER2-positive cancer, the cells make far too much HER2, and this signaling helps the cancer grow quickly. Pertuzumab is a monoclonal antibody, a lab-made immune protein designed to attach to one specific target. It binds to the part of HER2 that pairs with these partner receptors, which blocks the pairing and cuts off growth signals that would otherwise keep the cell multiplying or alive. It also marks the cancer cell so immune cells can attack it. Trastuzumab attaches to a different part of HER2 and disrupts its signaling in another way, so the two antibodies together block HER2 more completely than either does alone. Chemotherapy works alongside them by damaging rapidly dividing cells.
Perjeta is given as an infusion into a vein at a cancer treatment center, once every 3 weeks. The first dose is larger and runs over about 60 minutes; later doses take 30 to 60 minutes. On treatment days, trastuzumab and chemotherapy are given one after another, and staff watch for reactions for about an hour after the first pertuzumab infusion and about 30 minutes after later ones before the next drug starts. How long treatment lasts depends on the situation. Before surgery, it is usually given for 3 to 6 cycles. For early breast cancer, pertuzumab and trastuzumab are typically continued after surgery so that the total course reaches about one year (up to 18 cycles). For metastatic cancer, treatment generally continues as long as it keeps the cancer under control and side effects remain manageable. Phesgo is injected under the skin of the thigh by a health professional over about 8 minutes for the first dose and about 5 minutes after that, also every 3 weeks, with a shorter observation period afterward. Its doses differ from the IV products, so Phesgo, Perjeta and other trastuzumab-containing medicines are not swapped for one another. Before starting either product, the care team confirms the HER2 test result, checks heart function with a scan, and checks for pregnancy in anyone who could be pregnant.
Many of the side effects people notice come from the full combination, especially the chemotherapy. Diarrhea is the one most clearly linked to pertuzumab: in the main trial in metastatic cancer, about two in three people taking it had diarrhea, compared with fewer than half of those taking trastuzumab and chemotherapy alone, and it was occasionally severe. Diarrhea that keeps going or is hard to control is worth reporting promptly rather than waiting for the next visit. Hair loss, nausea, tiredness, rash, mouth sores and numbness or tingling in the hands and feet are also common, along with low white blood cell counts that raise the chance of infection. Reactions during or soon after a dose, such as fever, chills, headache or tiredness, happen in a minority of people. Serious allergic reactions, including anaphylaxis, are uncommon but can be life-threatening, which is why staff observe people after each dose. Swelling of the face, lips or throat, trouble breathing or chest pain after leaving the clinic needs immediate contact with the care team, and emergency care if breathing is difficult. Because pertuzumab can weaken the heart's pumping, new or worsening shortness of breath, cough, swelling of the ankles, legs or face, a racing or pounding heartbeat, weight gain of more than 5 pounds in a day, dizziness or fainting should be reported to the care team right away.
Pertuzumab carries two FDA boxed warnings, the agency's most prominent kind. The first is heart damage. It can reduce the strength of the heart's main pumping chamber, sometimes without symptoms and sometimes causing heart failure. In the main metastatic trial, about 4 percent of people developed weakened pumping and about 1 percent developed symptomatic heart failure. Heart function is measured before treatment and at regular intervals during it, and treatment is paused or stopped if pumping drops significantly. The risk is higher in people who have previously had anthracyclines (a group of chemotherapy drugs that includes doxorubicin and epirubicin) or radiation to the chest. When an anthracycline is part of the plan, pertuzumab and trastuzumab start only after it is finished. The second boxed warning concerns pregnancy. Pertuzumab with trastuzumab can cause birth defects or the death of a developing baby, including when exposure occurs within 7 months before conception. Anyone who could become pregnant needs a pregnancy test before starting and effective contraception during treatment and for 7 months after the last dose. A known or suspected pregnancy should be reported to the care team promptly. There is no information on whether pertuzumab passes into breast milk, so feeding plans are best discussed with the team, taking this 7-month washout period into account. People who have had an allergic reaction to pertuzumab or its ingredients should not receive it. The prescribing information does not list specific drug interactions, but the care team should still know about all other medicines and supplements.
Treatment means a visit every 3 weeks, along with regular heart scans and blood tests. The benefit depends on the setting. In metastatic breast cancer, adding pertuzumab to trastuzumab and docetaxel in a large trial extended the median time before the cancer worsened from about 12 months to about 18.5 months, and median survival from about 41 months to about 56.5 months. Median means half of people did better and half did worse, so individual results vary widely. Before surgery, the goal is to shrink the cancer, and success is often judged by whether any invasive cancer remains in the breast and lymph nodes removed at the operation. In one trial, about 39 percent of people given pertuzumab, trastuzumab and docetaxel had no remaining invasive cancer, compared with about 22 percent without pertuzumab. The improvement was smaller in hormone receptor-positive tumors, which are fueled partly by estrogen or progesterone. After surgery, the added benefit is real but small. In a trial of more than 4,800 people followed for about four years, invasive cancer returned or death occurred in 7.1 percent of those given pertuzumab compared with 8.7 percent of those given placebo, alongside trastuzumab and chemotherapy in both groups. The gain was concentrated in people whose cancer had reached the lymph nodes; those with node-negative cancer showed no clear benefit. This is why the decision to add pertuzumab after surgery often turns on how high an individual's risk of recurrence is.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Perjeta (Pertuzumab), what you've noticed, or ask the community a question.